Date: 10th June 2014
London, UK, 10th June 2014 – DNA Electronics Ltd (DNAe), a provider of point-of-care genomic diagnostics solutions for medical and healthcare applications, today announces the appointment of Nick McCooke as Chief Business Officer as it continues to build its management team.
Mr McCooke brings 30 years of senior management experience in Healthcare businesses. As CEO of Solexa, from its spin-out from the University of Cambridge in 2000 to its NASDAQ listing in 2005, he led the development of the world’s leading Next Generation DNA Sequencing (NGS) technology, which is the basis of Illumina’s current product line.
Mr McCooke comments: “I’m thrilled to be joining DNAe at this exciting point in the company’s evolution. I was proud to be part of the NGS revolution ten years ago and I believe that bringing the technology to clinicians at the point of need is the next revolution.”
CEO and Chairman Prof. Chris Toumazou adds: “This is a key appointment for DNAe, as we build a world-class management team to bring our Genalysis® molecular diagnostics platform to market. Nick’s experience, both in NGS technology and in the diagnostics markets will help us to develop ground-breaking new products that give clinicians rapid actionable diagnosis of life-threatening conditions.”
Members of the media interested in scheduling a briefing with DNA Electronics’ new CBO Nick McCooke can do so by contacting Claire Furner at claire[at]evokedset[dot]com
-- ends –
Notes to editors:
About DNA Electronics:
DNA Electronics is a developer of semiconductor solutions for real-time nucleic acid detection which enables faster, simpler and more cost-effective DNA analysis platforms.
A spin-out of Imperial College London, DNA Electronics was founded by Professor Toumazou following his invention of the company’s core technology that allows CMOS transistors to be switched on and off with DNA – the key invention enabling semiconductor-based sequencing. Prof. Toumazou’s innovation has culminated in the world’s first DNA logic on standard CMOS technology.
The company’s IP portfolio includes techniques for monitoring nucleotide insertions using ion-sensitive transistors, enabling label-free electronic DNA sequencing and diagnostics platforms. DNA Electronics (DNAe) has developed the ground-breaking Genalysis® platform of disposable silicon chip-based solutions for real-time nucleic acid sequence detection at the point of care, providing end users with technology as yet unavailable outside a laboratory.
DNA Electronics has a non-exclusive, field-limited licensing agreement with Ion Torrent (now part of Thermo Fisher Scientific), whose next generation sequencing technology is based on DNA Electronics’ semiconductor sequencing IP. DNA Electronics has also licensed its Genalysis® technology platform to GENEU™, a company that is delivering on-the-spot genetic analytics services for cosmetics and skincare applications.
For more information: http://www.dnae.co.uk
PRESS CONTACT for DNA Electronics:
Claire Furner, EvokedSet
Mobile: +44 (0)7539 862893